Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled parallel design Phase 2A study investigating the efficacy of PH10, a novel intranasal spray, in patients with major depressive disorder

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled parallel design Phase 2A study investigating the efficacy of PH10, a novel intranasal spray, in patients with major depressive disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Itruvone (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Pherin Pharmaceuticals

    • Most Recent Events

    • 17 Jul 2023 Results presented in the VistaGen Therapeutics Media Release.
    • 21 Jun 2023 Results of this trial assessing the efficacy and safety, presented in a VistaGen Therapeutics media release.
    • 06 Dec 2022 According to a VistaGen Therapeutics media release, based on the nonclinical studies and three prior clinical studies of PH10, including this Phase 2A clinical study, the USA Food and Drug Administration (FDA) has granted Fast Track designation for the development of PH10 for the treatment of major depressive disorder (MDD).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top